Skip to content

Phase I-II Trail of Escalated Fractionated Dose Intensity Modulated Radiotherapy in Locally Advanced Laryngo-Hypopharyngeal Squamous Cell Carcinomas

Phase I-II Trail of Escalated Fractionated Dose Intensity Modulated Radiotherapy in Locally Advanced Laryngo-Hypopharyngeal Squamous Cell Carcinomas

Status
Active, not recruiting
Phases
Phase 2
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-ONRC-14004240
Enrollment
Unknown
Registered
2014-01-26
Start date
2013-02-15
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Squamous cell cancer of the larynx and hypopharynx

Interventions

1:69Gy/30F radical IMRT
2:70Gy/33F radical IMRT

Sponsors

Department of Radiation Oncology, Chinese PLA General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Aged from 18 to 75; 2. The pathological diagnosis is squamous cell carcinoma; 3. Patients diagnosed cancer of the larynx and hypopharynx are staged retrospectively from III to IV B, in accordance with the American Joint Committee on Cancer 2010 criteria. Or refuse operation; 4. Normal blood picture and hepatorenal function; 5. NO severe and /or uncontrolled medical conditions, including severe cardiovascular disease, uncontrolled diabetes and high blood pressure, active infection, liver and kidney disorders; 6. No second primary carcinoma; 7. Karnofsky scoring function from 60 to 100.

Exclusion criteria

Exclusion criteria: 1. Severe and /or uncontrolled medical conditions, including severe cardiovascular disease, uncontrolled diabetes and high blood pressure, active infection, liver and kidney disorders; 2. Patients in pregnant or nursing; 3. Received any surgical operation or radiotherapy; 4. Patient with uncontrollable mental disease and active infection; 5. Documented hypersensitivity reaction to paclitaxel or taxinol; 6. Patient with lower compliance; 7. Patient not fitted for this study determined by the principal investigator (PI).

Design outcomes

Primary

MeasureTime frame
ORR;PFS;

Countries

China

Contacts

Public ContactLin Ma

Department of Radiation Oncology, Chinese PLA General Hospital

malinpharm@sina.com+86 13911197589

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026